Skip to main content
Medical information Clinical review pending

Diagnostic Testing

Immunophenotyping By Flow Cytometry CD103 Test

The Immunophenotyping By Flow Cytometry CD103 Test helps identify specific immune cells, aiding in the diagnosis and management of certain cancers. This test analyzes cell surface markers using flow cytometry.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
3 mL (2 mL min.) whole blood in one Lavender Top (EDTA) tube and 3 mL (2 mL min.) whole blood in one Green Top (Sodium Heparin) tube. Alternatively, 2 mL (1 mL min.) of bone marrow in a Green Top (Sodium Heparin) tube.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Please ensure the sample collection tubes are correctly filled and labelled.
Test priceKSh 7,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Immunophenotyping By Flow Cytometry CD103 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of certain hematological malignancies
  • ✓Characterization of immune cell populations
  • ✓Monitoring disease progression
  • ✓Guiding treatment decisions
  • ✓Evaluation of patients with unexplained symptoms suggestive of cancer
  • ✓Risk assessment for individuals with family history of cancer
02

In plain language

What this test helps you understand

This test aids in the diagnosis, classification, and monitoring of certain hematological malignancies by identifying specific immune cell populations based on CD103 expression.
The Immunophenotyping By Flow Cytometry CD103 Test is a diagnostic procedure used to identify and characterize specific immune cells, particularly in the context of cancer. It utilizes flow cytometry technology to analyze cell surface markers, providing valuable information for healthcare professionals.

This test measures the expression of the CD103 marker on immune cells. The presence or level of this marker can be significant in identifying certain types of T-cells associated with various cancers. Evaluating these markers helps clinicians understand the patient's immune status and the nature of potential malignancies.

Patients experiencing symptoms like unexplained weight loss, persistent fatigue, or recurrent infections might be advised to consider this test. Individuals with risk factors for hematological cancers, such as a family history or previous cancer diagnoses, may also benefit from this evaluation.

Benefits of this test include aiding in the accurate diagnosis of hematological malignancies, helping determine effective treatment strategies, monitoring disease progression, and supporting personalized medicine approaches.

Results will be interpreted by qualified healthcare professionals. A detailed report will indicate the presence or absence of the CD103 marker. Discuss your results with your doctor to understand their implications fully.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Please ensure the sample collection tubes are correctly filled and labelled.
Sample3 mL (2 mL min.) whole blood in one Lavender Top (EDTA) tube and 3 mL (2 mL min.) whole blood in one Green Top (Sodium Heparin) tube. Alternatively, 2 mL (1 mL min.) of bone marrow in a Green Top (Sodium Heparin) tube.
MethodologyFlow Cytometry
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test identifies the presence or absence of the CD103 marker. Results must be interpreted in the context of the patient's clinical presentation, medical history, and other laboratory findings. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Immunophenotyping is a laboratory technique used to identify cells based on the molecules (markers) they display on their surface or inside them.
The CD103 marker is found on certain types of immune cells. Its presence or level can be associated with specific conditions, including certain cancers.
A blood sample or a bone marrow sample is required for this test. Specific instructions regarding the type and volume of sample are provided.
Results are interpreted by qualified healthcare professionals, such as oncologists or hematologists, in conjunction with your clinical information.
Generally, no specific preparation is needed for the sample collection itself. Follow the instructions provided by the laboratory regarding sample handling.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp